Metformin — Research Protocol

⚠️ RESEARCH SUMMARY — NOT A TREATMENT PROTOCOL. Discuss all findings with your healthcare provider.

Metformin is under investigation for longevity (TAME trial) and cancer prevention. Dosing regimens in published literature vary. This page summarizes published research protocols. It is not a guide for self-treatment. Discuss any treatment decisions with your physician.

Research Dosing (from Published Studies)

ContextDoseRouteFrequencyNotes
TAME trial (longevity)Dosing regimens in published literature vary — consult the cited studies for detailsOralSee cited trialTargeting Aging with Metformin. Primary endpoint: composite of age-related diseases. Published studies have investigated various dosing approaches.
Cancer prevention (epidemiological)Dosing regimens in published literature vary — consult the cited studies for detailsOralSee cited trialEpidemiological data has reported 30-40% cancer risk differences in diabetic patients on metformin. Causality not established.
Exercise interaction noteN/AN/AN/AMASTERS trial reported that metformin may blunt some exercise-induced skeletal muscle adaptations. See the cited study for details.

Pharmacokinetics

Oral bioavailability 50-60%. Not metabolized — excreted unchanged by kidneys. Half-life 4-8.7 hours. Extended-release formulations improve GI tolerability. Steady-state reached in 24-48 hours.

Safety Profile

GI side effects (diarrhea, nausea, bloating) in 20-30% — usually transient with gradual dose titration. Vitamin B12 deficiency with long-term use (~6-9% of patients). Rare: lactic acidosis (0.03 per 1000 patient-years, primarily in renal impairment).

Contraindications

Monitoring Parameters

View Metformin glossary entry →